Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human Primates
Changyu Wang, Kent Thudium, Minhua Han, et al.
Cancer Immunology Research (2014) Vol. 2, Iss. 9, pp. 846-856
Open Access | Times Cited: 555

Showing 1-25 of 555 citing articles:

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 17, pp. 1627-1639
Open Access | Times Cited: 8738
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 2, pp. 123-135
Open Access | Times Cited: 7956
Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
Caroline Robert, Georgina V. Long, Benjamin Brady, et al.
New England Journal of Medicine (2014) Vol. 372, Iss. 4, pp. 320-330
Open Access | Times Cited: 5052
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, et al.
The Lancet (2021) Vol. 398, Iss. 10294, pp. 27-40
Open Access | Times Cited: 2008
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
American Journal of Clinical Oncology (2015) Vol. 39, Iss. 1, pp. 98-106
Open Access | Times Cited: 1947
Development of therapeutic antibodies for the treatment of diseases
Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 1739
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 18, pp. 2004-2012
Open Access | Times Cited: 1135
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 7, pp. 785-792
Closed Access | Times Cited: 1058
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 11, pp. 1506-1517
Closed Access | Times Cited: 997
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero, David M. Berman, M. Ángela Aznar, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 8, pp. 457-472
Closed Access | Times Cited: 600
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Sean P. Arlauckas, Christopher Garris, Rainer H. Köhler, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 389
Open Access | Times Cited: 563
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott
Clinical Therapeutics (2015) Vol. 37, Iss. 4, pp. 764-782
Open Access | Times Cited: 533
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O’Donnell, Georgina V. Long, Richard A. Scolyer, et al.
Cancer Treatment Reviews (2016) Vol. 52, pp. 71-81
Closed Access | Times Cited: 505
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 25, pp. 2980-2987
Open Access | Times Cited: 480
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David R. Minor, Sandra P. D’Angelo, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 4, pp. 383-390
Open Access | Times Cited: 468
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary, Eyad Elkord
Vaccines (2016) Vol. 4, Iss. 3, pp. 28-28
Open Access | Times Cited: 436
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams, James Smothers, Roopa Srinivasan, et al.
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 9, pp. 603-622
Closed Access | Times Cited: 432
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott, Charles G. Drake, Mario Sznol, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 18, pp. 2013-2020
Open Access | Times Cited: 430
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 25, pp. 2969-2979
Open Access | Times Cited: 419
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Daniel G. Coit, John A. Thompson, Mark R. Albertini, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 4, pp. 367-402
Open Access | Times Cited: 405
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, et al.
Cancer Immunology Research (2015) Vol. 4, Iss. 2, pp. 124-135
Open Access | Times Cited: 387
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 7, pp. 509-528
Closed Access | Times Cited: 376
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu‐Monette, Jianfeng Zhou, Ken H. Young
Blood (2017) Vol. 131, Iss. 1, pp. 68-83
Open Access | Times Cited: 369
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 7, pp. 943-955
Open Access | Times Cited: 317
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A. Ajani, Markus Moehler, et al.
Nature (2022) Vol. 603, Iss. 7903, pp. 942-948
Open Access | Times Cited: 315
Page 1 - Next Page

Scroll to top